Quanterix Faces Nasdaq Compliance Challenge Due to Financial Restatement Efforts

Quanterix Faces Compliance Challenge Amid Financial Restatement Efforts

Quanterix Corporation, a leader in high-sensitivity biomarker detection technology, receives a notification from The Nasdaq Stock Market regarding its non-compliance with listing rules due to a delay in filing its Quarterly Report on Form 10-Q for the period ending September 30, 2024. The notification, dated November 21, 2024, indicates that the company has a 60-day period, until January 20, 2025, to submit a plan demonstrating how it intends to regain compliance. While this notice is a routine procedure for delayed filings and does not immediately affect the trading of Quanterix's common stock, it underscores the importance of timely financial reporting for maintaining investor confidence and market integrity.

The root cause of this delay stems from Quanterix's need to restate its audited consolidated financial statements for the fiscal years ending December 31, 2023, and 2022. Additionally, the company must revise its unaudited consolidated financials for several quarters spanning from March 2022 to June 2024. This comprehensive restatement process reflects the company's commitment to ensuring accurate and transparent financial reporting, which is crucial for its reputation and operational stability. In light of this development, Quanterix is actively working to finalize the Form 10-Q and complete all necessary filings by the end of 2024, demonstrating its proactive approach to addressing the situation.

Quanterix's Simoa® technology, renowned for its ability to detect biomarkers with unprecedented sensitivity, remains a cornerstone of its operations and innovation. The company has established itself as a significant contributor to scientific research, with over 3,100 peer-reviewed publications that highlight its role in advancing medical understanding in fields such as neurology, oncology, and infectious diseases. This expertise positions Quanterix as a valuable partner within the scientific community, even as it navigates its current compliance challenges.

In addition to addressing its financial reporting issues, Quanterix invites stakeholders and interested parties to stay informed about its developments through its website and social media channels. The company’s commitment to transparency and collaboration continues to underpin its operations, as it strives to uphold its standing in the biomarker detection industry while meeting regulatory requirements.